Equifax
EFX
$181.90
-1.34%
Equifax is one of the three dominant credit bureaus in the United States, providing critical consumer credit reports and analytics that underpin lending decisions. The company has diversified its revenue streams, with a significant portion derived from workforce solutions for income verification and human resources services, and maintains a notable international presence. The current investor narrative is dominated by the stock's significant underperformance relative to the broader market, reflecting concerns over competitive pressures, particularly from fintech and AI-driven lending platforms, as well as potential cyclical headwinds in credit-sensitive sectors.…
EFX
Equifax
$181.90
Related headlines
Investment Opinion: Should I buy EFX Today?
Rating & Thesis: Hold. Equifax is a financially sound company caught in a negative narrative spiral, with its current valuation offering a balanced risk/reward but lacking a near-term catalyst for outperformance. The limited analyst data shows a cautiously positive bias, but no clear price target is available to anchor an upside calculation.
Supporting Evidence: The forward P/E of 17.6x appears reasonable if the company can achieve its estimated EPS of $16.91, representing a significant earnings ramp. Revenue, while decelerating, still grew 9.24% YoY in Q4 2025. Profitability remains solid with an operating margin of 18.0% and ROE of 14.3%. Most importantly, the company's strong free cash flow generation of $1.13 billion TTM provides a fundamental floor and supports shareholder returns.
Risks & Conditions: The two biggest risks are the persistence of the revenue growth deceleration and the materialization of competitive threats from AI-driven platforms. This Hold rating would upgrade to a Buy if the stock breaks below $170 (offering a greater margin of safety) while forward earnings estimates hold, or if quarterly revenue growth re-accelerates above 12%. It would downgrade to a Sell if the stock breaks below its 52-week low on deteriorating fundamentals or if forward EPS estimates are cut meaningfully. The stock is fairly valued relative to its forward earnings potential but remains overvalued on a trailing basis given its growth challenges.
Sign up to view all
EFX 12-Month Price Forecast
The analysis adopts a neutral stance based on conflicting signals: attractive forward valuation versus deteriorating price momentum and growth trajectory. The high beta of 1.56 adds to the uncertainty, making the stock a leveraged bet on the resolution of its competitive and cyclical concerns. Confidence is medium because while the cash flow profile is robust, the near-term catalyst for a re-rating is not visible. The stance would upgrade to bullish on evidence of stabilizing or re-accelerating organic revenue growth. It would turn bearish on a breakdown below the $166 support level on high volume, signaling a new leg down in the fundamental story.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Equifax's 12-month outlook, with a consensus price target around $236.47 and implied upside of +30.0% versus the current price.
Average Target
$236.47
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$146 - $236
Analyst target range
Analyst coverage for EFX appears limited in the provided dataset, with only 6 analysts cited for EPS estimates, and no explicit consensus price target, recommendation breakdown, or target range is available in the data inputs. Therefore, insufficient analyst coverage data is available to provide a meaningful consensus sentiment, target price, or implied upside/downside calculation. The lack of comprehensive coverage data could indicate the stock, despite its market cap, may have less consistent institutional tracking, which can contribute to higher volatility and less efficient price discovery. The available institutional ratings from recent months show a mix of actions, including 'Overweight' from Morgan Stanley, JP Morgan, and Wells Fargo, 'Buy' from Stifel and Needham, and 'Equal Weight' from Barclays, suggesting a generally positive but cautious bias among those firms.
Bulls vs Bears: EFX Investment Factors
The bear case currently holds stronger evidence, driven by the stock's severe technical breakdown, significant market underperformance, and clear signs of revenue growth deceleration. The bull case rests on a valuation reset (forward P/E of 17.6x) and the company's resilient cash generation. The single most important tension in the investment debate is whether Equifax's forward earnings estimates—which imply a significant recovery—are achievable amidst rising competitive threats and a potential cyclical slowdown, or if they will be revised downward, making the current forward multiple misleadingly cheap.
Bullish
- Strong Free Cash Flow Generation: Equifax generates robust free cash flow, with TTM FCF of $1.13 billion. This provides significant financial flexibility to fund dividends, share buybacks, and debt service, supporting shareholder returns even during a challenging period.
- Attractive Forward Valuation: The stock trades at a forward P/E of 17.6x, which is a significant discount to its trailing P/E of 40.5x. This forward multiple suggests the market has already priced in a substantial earnings recovery, offering a potential entry point if forecasts are met.
- Diversified Revenue Streams: The company has successfully diversified beyond core credit reporting, with Workforce Solutions contributing $1.30 billion annually and International generating $0.72 billion. This reduces reliance on cyclical U.S. credit activity and provides multiple growth engines.
- Solid Profitability Metrics: Despite revenue growth concerns, the company maintains solid profitability with a Q4 2025 operating margin of 18.0% and an ROE of 14.3%. These metrics indicate efficient operations and reasonable returns on shareholder capital.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is in a pronounced downtrend, down 26.3% over the past year versus the S&P 500's 22.2% gain, a relative underperformance of -48.5. Trading just 15% above its 52-week low of $166.02, the chart reflects persistent and accelerating selling pressure.
- Revenue Growth Deceleration: Q4 2025 revenue grew 9.24% YoY, but sequential quarterly revenue from Q1 to Q4 2025 ($1.44B, $1.54B, $1.54B, $1.55B) shows growth plateauing in the second half. This deceleration validates concerns about competitive and cyclical pressures.
- High Trailing Valuation & Elevated Beta: A trailing P/E of 40.5x is elevated, especially for a company with decelerating growth. Coupled with a beta of 1.56, the stock is over 50% more volatile than the market, amplifying downside risk in a risk-off environment.
- Competitive Threat from Fintech/AI: The investor narrative is dominated by competitive pressures from fintech and AI-driven lending platforms, as highlighted in recent news. This threatens Equifax's moat in its core credit analytics business and could pressure long-term growth rates and margins.
EFX Technical Analysis
The stock is in a pronounced and sustained downtrend, evidenced by a 1-year price change of -26.33%, significantly underperforming the S&P 500's 22.2% gain. With a current price of $182.39, it is trading near the lower end of its 52-week range of $166.02 to $281.03, positioning it at approximately 15% above the 52-week low. This proximity to multi-year lows suggests the market is pricing in substantial fundamental concerns, though it may also attract value-oriented investors if the business stabilizes. Recent momentum remains deeply negative, with the stock down 11.65% over the past month and 14.78% over the past three months, indicating the selling pressure is persistent and accelerating relative to the longer-term downtrend. This divergence from the market is stark, as shown by a relative strength of -48.53 over one year and -10.78 over three months. Key technical levels are clearly defined, with immediate support at the 52-week low of $166.02 and resistance far above near the 52-week high of $281.03. A decisive break below $166 would signal a new leg down, while any recovery would need to overcome significant overhead supply. The stock's beta of 1.56 confirms it is over 50% more volatile than the market, which amplifies both downside risk and potential upside moves, demanding careful risk management.
Beta
1.56
1.56x market volatility
Max Drawdown
-39.6%
Largest decline past year
52-Week Range
$166-$281
Price range past year
Annual Return
-19.0%
Cumulative gain past year
| Period | EFX Return | S&P 500 |
|---|---|---|
| 1m | -7.2% | +0.4% |
| 3m | -19.9% | -2.0% |
| 6m | -21.0% | +4.1% |
| 1y | -19.0% | +23.9% |
| ytd | -15.0% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EFX Fundamental Analysis
Revenue growth has been positive but appears to be decelerating; the most recent Q4 2025 revenue was $1.55 billion, representing a year-over-year growth of 9.24%. However, examining the sequential quarterly revenue from Q1 to Q4 2025 ($1.44B, $1.54B, $1.54B, $1.55B) shows growth plateauing in the second half of the year. Segment data indicates the U.S. Consumer Information Solutions business generated $3.09 billion annually, Workforce Solutions $1.30 billion, and International $0.72 billion, with the core U.S. credit segment being the largest driver. The company remains profitable, with Q4 2025 net income of $175.7 million and a net margin of 11.33%. Gross margin for the quarter was 44.60%, though it showed significant quarterly volatility (e.g., 54.46% in Q1 2025 vs. 10.96% in Q4 2025, likely due to cost recognition differences). Operating margin for Q4 2025 was 18.03%, indicating solid operational efficiency. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.11, and the company generates substantial cash flow, with trailing twelve-month free cash flow of $1.13 billion. The current ratio of 0.60 suggests relatively tight liquidity, though this is common for asset-light data businesses. An ROE of 14.34% indicates reasonable returns on shareholder capital, supported by the strong free cash flow generation which provides flexibility for dividends, buybacks, and debt service.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.10%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EFX Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 40.48x, while the forward PE is significantly lower at 17.61x, indicating the market expects a substantial recovery in earnings over the next twelve months. Compared to sector averages, the trailing PE of 40.48x is likely at a premium to the broader Industrials/Consulting Services sector, though a direct industry average is not provided in the data. The forward multiple suggests the premium may compress if earnings forecasts are met. Historically, the stock's own PE ratio has fluctuated widely; the current trailing PE of 40.48x is above the recent historical range seen in the provided data (e.g., 37.48x at end-2025, up to 64.45x in early 2024). Trading near the higher end of its own recent historical band suggests the market is still pricing in a relatively optimistic earnings recovery scenario despite the severe price decline, implying expectations are high and leave little room for disappointment.
PE
40.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Equifax faces risks from its elevated trailing valuation (P/E of 40.5x) which demands sustained high growth, a scenario now in question as revenue growth decelerates to a plateau. The company carries moderate financial leverage with a debt-to-equity ratio of 1.11, and a current ratio of 0.60 indicates relatively tight liquidity, though this is mitigated by strong annual free cash flow of $1.13 billion. Earnings volatility is evident in the fluctuating quarterly gross margins (from 54.5% in Q1 2025 to 11.0% in Q4 2025), though this may be due to cost recognition timing.
Market & Competitive Risks: The primary external threat is disruptive competition from fintech and AI-driven lending platforms, which could erode Equifax's pricing power and market share in its core credit analytics business. Trading at a premium trailing P/E during a growth deceleration phase presents a significant valuation compression risk. The stock's high beta of 1.56 makes it acutely sensitive to broader market downturns and sector rotation away from growth-oriented names, as evidenced by its drastic underperformance versus the S&P 500.
Worst-Case Scenario: The worst-case scenario involves a combination of a deep cyclical downturn in credit-sensitive sectors, accelerated market share loss to AI-driven competitors, and a subsequent sharp downward revision to forward earnings estimates. This could trigger a re-rating to a distressed multiple. A realistic downside target is a retest and break below the 52-week low of $166.02, representing a potential loss of approximately -9% from the current price of $182.39. In a more severe scenario mirroring the stock's maximum drawdown of -39.6%, the price could fall towards $110, though this would require a fundamental crisis.
FAQ
The key risks are, in order of severity: 1) Competitive Disruption: Fintech and AI-driven platforms (like Upstart) threatening its core credit analytics business, potentially eroding pricing and market share. 2) Cyclical & Execution Risk: Revenue growth has decelerated to a plateau; an economic slowdown could further reduce credit inquiry volumes. 3) Valuation & Volatility Risk: The high trailing P/E (40.5x) and beta (1.56) make the stock vulnerable to multiple compression and amplified downside moves in a bear market. 4) Financial Risk: While manageable, a debt-to-equity ratio of 1.11 and a low current ratio of 0.60 indicate reliance on stable cash flows.
The 12-month forecast is bifurcated. The base case (55% probability) sees the stock trading between $190 and $220 as it stabilizes, supported by its forward P/E but capped by growth concerns. The bull case (25% probability) targets a range of $240 to $281 if earnings estimates are beaten and competitive fears fade. The bear case (20% probability) envisions a retest of the 52-week low, with a range of $166 to $180, driven by earnings misses and estimate cuts. The base case is most likely, predicated on the assumption that the company's strong cash flow prevents a fundamental crisis but growth remains subdued.
EFX sends mixed valuation signals. On a trailing basis, it appears overvalued with a P/E of 40.5x, especially given its growth challenges. However, the forward P/E of 17.6x, based on estimated EPS of $16.91, suggests the market is pricing in a substantial earnings recovery and may be fairly valued or even slightly undervalued if those estimates are met. The key is that the valuation is entirely dependent on future earnings growth materializing. Compared to its own historical P/E range (which has been as high as 64x), the current multiple is lower, but this reflects a degraded growth outlook.
EFX presents a high-risk, moderate-reward opportunity at current levels. For investors with a high risk tolerance and a long-term horizon, the forward P/E of 17.6x and strong free cash flow may be appealing. However, given the severe technical downtrend (-26.3% over the past year), decelerating revenue growth, and significant competitive overhang, it is not a good buy for conservative investors or those seeking near-term gains. It could be a good buy for a contrarian, value-focused portfolio if purchased in stages, with a strict stop-loss below the $166 support level.
EFX is unsuitable for short-term trading due to its high volatility (beta 1.56) and lack of a clear near-term catalyst. The severe downtrend suggests catching a falling knife is risky. It is more appropriate for a long-term investment horizon of 3-5 years, allowing time for the company to navigate competitive threats, potentially reinvigorate growth, and for the valuation to normalize. The modest dividend yield of 0.87% offers a small income component, but this is primarily a capital appreciation story dependent on a successful business turnaround. A minimum holding period of 18-24 months is suggested to assess whether the growth deceleration has truly bottomed.